Edmondson Dale E, Binda Claudia, Wang Jin, Upadhyay Anup K, Mattevi Andrea
Department of Biochemistry, Emory University, Atlanta, Georgia 30322, USA.
Biochemistry. 2009 May 26;48(20):4220-30. doi: 10.1021/bi900413g.
The past decade has brought major advances in our knowledge of the structures and mechanisms of MAO A and MAO B, which are pharmacological targets for specific inhibitors. In both enzymes, crystallographic and biochemical data show their respective C-terminal transmembrane helices anchor the enzymes to the outer mitochondrial membrane. Pulsed EPR data show both enzymes are dimeric in their membrane-bound forms with agreement between distances measured in their crystalline forms. Distances measured between active site-directed spin-labels in membrane preparations show excellent agreement with those estimated from crystallographic data. Our knowledge of requirements for development of specific reversible MAO B inhibitors is in a fairly mature status. Less is known regarding the structural requirements for highly specific reversible MAO A inhibitors. In spite of their 70% level of sequence identity and similarities of C(alpha) folds, the two enzymes exhibit significant functional and structural differences that can be exploited in the ultimate goal of the development of highly specific inhibitors. This review summarizes the current structural and mechanistic information available that can be utilized in the development of future highly specific neuroprotectants and cardioprotectants.
在过去十年中,我们对单胺氧化酶A(MAO A)和单胺氧化酶B(MAO B)的结构及作用机制有了重大进展,它们是特定抑制剂的药理学靶点。在这两种酶中,晶体学和生物化学数据表明,它们各自的C末端跨膜螺旋将酶锚定在外膜线粒体膜上。脉冲电子顺磁共振(EPR)数据表明,这两种酶在膜结合形式下均为二聚体,其晶体形式下测得的距离相互吻合。在膜制剂中,活性位点定向自旋标记之间测得的距离与晶体学数据估计的距离高度吻合。我们对开发特定可逆MAO B抑制剂的要求的了解处于相当成熟的状态。对于高度特异性可逆MAO A抑制剂的结构要求,我们了解得较少。尽管这两种酶的序列一致性水平为70%,且α-碳折叠相似,但它们在功能和结构上仍存在显著差异,这些差异可用于开发高度特异性抑制剂这一最终目标。本综述总结了目前可用于开发未来高度特异性神经保护剂和心脏保护剂的结构和机制信息。